Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tozinameran + elasomeran
- Development stage
- Phase 4
- Lead developer
- Pfizer
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
Tozinameran + elasomeran refers to the combination or sequential use of the two primary mRNA-based COVID-19 vaccines: Pfizer-BioNTech's Comirnaty (tozinameran) and Moderna's Spikevax (elasomeran). This combination is most frequently encountered in the context of heterologous mix-and-match vaccination regimens, where an individual receives a primary series or booster dose of one vaccine followed by the other. Both components function by delivering nucleoside-modified messenger RNA (mRNA) encapsulated in lipid nanoparticles (LNPs) to host cells. The mRNA encodes the SARS-CoV-2 spike (S) protein, which is then expressed by the host's cellular machinery to elicit neutralizing antibodies and T-cell-mediated immune responses against the virus. While developed by different sponsors (Pfizer/BioNTech and Moderna, respectively), they share a similar mechanism of action and have been studied together in clinical trials to evaluate the safety and immunogenicity of heterologous boosting.
- Other names
- Pfizer-BioNTech COVID-19 VaccineModerna COVID-19 Vaccinetozinameran and elasomeran
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on tozinameran + elasomeran.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tozinameran + elasomeran.